Whatever the route of administration, the drug candidate in hearing loss or tinnitus has to reach its target, the inner ear, at the desired concentration. CILcare’s PK studies allow to assess the bioavailability of the candidate in the inner ear, to determine its kinetic profile, and to estimate the best time-point and concentration for dosing in a following efficacy study.


  • Route of administration: local (transtympanic, intrabullar, intracochlear, round window niche) and systemic (PO, IP, IV, SC)
  • Samplings: inner ear liquid, tympanic bulla, CSF, different brain structures, plasma
  • Bioanalysis

Basic concept of transtympanic treatment